Cellid, Co., Ltd. (299660.KQ)
KRW 5500.0
(-7.25%)
KRW 5500.0
(-7.25%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1078.05 KRW | 49.65% |
| 2022 | -2141.24 KRW | -74.59% |
| 2021 | -1226.46 KRW | -214.54% |
| 2020 | -389.92 KRW | -61.04% |
| 2019 | -242.12 KRW | 75.29% |
| 2018 | -979.71 KRW | -108.68% |
| 2017 | -469.47 KRW | -205.29% |
| 2016 | -153.78 KRW | -41.62% |
| 2015 | -108.59 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -241.94 KRW | -137.5% |
| 2024 Q2 | -192.08 KRW | 20.61% |
| 2023 Q1 | -331.92 KRW | 64.32% |
| 2023 FY | - KRW | 49.65% |
| 2023 Q4 | -101.87 KRW | 67.46% |
| 2023 Q3 | -313.05 KRW | 7.36% |
| 2023 Q2 | -337.93 KRW | -1.81% |
| 2022 Q4 | -930.33 KRW | -152.46% |
| 2022 FY | - KRW | -74.59% |
| 2022 Q1 | -406.25 KRW | 0.43% |
| 2022 Q3 | -368.50 KRW | -4.89% |
| 2022 Q2 | -351.33 KRW | 13.52% |
| 2021 Q3 | -244.93 KRW | -7.4% |
| 2021 Q4 | -408.02 KRW | -66.59% |
| 2021 Q1 | -271.98 KRW | -64.2% |
| 2021 Q2 | -228.05 KRW | 16.15% |
| 2021 FY | - KRW | -214.54% |
| 2020 Q4 | -165.64 KRW | -33.58% |
| 2020 Q1 | -142.00 KRW | -80.62% |
| 2020 Q2 | 4.00 KRW | 102.82% |
| 2020 Q3 | -124.00 KRW | -3200.0% |
| 2020 FY | - KRW | -61.04% |
| 2019 Q1 | -48.00 KRW | 56.25% |
| 2019 FY | - KRW | 75.29% |
| 2019 Q4 | -78.62 KRW | -28.89% |
| 2019 Q3 | -61.00 KRW | 19.74% |
| 2019 Q2 | -76.00 KRW | -58.33% |
| 2018 Q2 | -342.00 KRW | 73.39% |
| 2018 FY | - KRW | -108.68% |
| 2018 Q1 | -1285.00 KRW | -64.82% |
| 2018 Q4 | -109.71 KRW | 0.0% |
| 2017 FY | - KRW | -205.29% |
| 2017 Q1 | -221.00 KRW | 0.0% |
| 2017 Q4 | -779.65 KRW | 0.0% |
| 2016 FY | - KRW | -41.62% |
| 2015 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Sam Chun Dang Pharm. Co., Ltd | -463.03 KRW | -132.825% |
| Hyundai Bioscience Co., Ltd. | -365.00 KRW | -195.356% |
| ST Pharm Co.,Ltd. | 1041.07 KRW | 203.552% |
| ABL Bio Inc. | -55.32 KRW | -1848.753% |